Summary: Learn about the major achievements in the gene therapy market in 2023, with a focus on reliable manufacturing processes and strategies to enhance predictability while reducing waste in gene therapy manufacturing.

Summary: Learn about the major achievements in the gene therapy market in 2023, with a focus on reliable manufacturing processes and strategies to enhance predictability while reducing waste in gene therapy manufacturing.

Here we present an in-line cell lysis assembly developed at Catalent to increase throughput while controlling critical parameters such as time of contact and solutions ratio, delivering a high-quality product.

Summary: In a recent presentation during the 2024 JP Morgan Healthcare Conference, Catalent’s Group President of Biologics Dave McErlane addresses the latest market drivers for Biologics and Sterile Injectables.

In this article, Catalent's experts detail a scalable approach to fast-tracking AAVs with integrated solutions, from clonal cell-lines to market.

Catalent's UpTempo AAV platform process offers clients accelerated timelines for producing their clinical materials. The scalable, CGMP-ready platform process can significantly reduce the time from gene to clinic through a simplified supply chain.

Catalent experts discuss UpTempo℠ AAV, a one-stop integrated viral vector platform for speed to clinic. Discover how implementing the right process, utilizing a clonal HEK293 cell line, and leveraging a range of off-the-shelf plasmids, along with qualified analytical methods, can support a robust supply chain for the development and manufacture of AAV vectors.

In recent years, the field of gene therapy has witnessed remarkable achievements and advancements. These breakthroughs have brought us even closer to unleashing the full potential of gene therapies. Catalent gene therapy experts discuss all aspects of gene therapy commercialization in depth.

In this fireside chat, George Buchman, Ph.D., Vice President, Pre-Clinical and Process Development, Catalent Cell & Gene Therapy and Thomas VanCott, Ph.D., Chief Scientific Officer, Combined Therapeutics, explore how a complete platform approach to fast-track AAVs can enhance quality and efficiency.

Learn how the right process, clonal HEK293 cell line, and range of off-the-shelf plasmids, along with qualified analytical methods supports a robust supply chain for the development and manufacture of AAV vectors, and the reduction of timelines to clinical evaluation.